{"doc_id": "32673060", "type of study": "Therapy", "title": "", "abstract": "Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 A Randomized Trial.\nNo effective oral therapy exists for early coronavirus disease 2019 (COVID-19).\nTo investigate whether hydroxychloroquine could reduce COVID-19 severity in adult outpatients.\nRandomized, double-blind, placebo-controlled trial conducted from 22 March through 20 May 2020. (ClinicalTrials.gov: NCT04308668).\nInternet-based trial across the United States and Canada (40 states and 3 provinces).\nSymptomatic, nonhospitalized adults with laboratory-confirmed COVID-19 or probable COVID-19 and high-risk exposure within 4 days of symptom onset.\nOral hydroxychloroquine (800 mg once, followed by 600 mg in 6 to 8 hours, then 600 mg daily for 4 more days) or masked placebo.\nSymptoms and severity at baseline and then at days 3, 5, 10, and 14 using a 10-point visual analogue scale.\nThe primary end point was change in overall symptom severity over 14 days.\nOf 491 patients randomly assigned to a group, 423 contributed primary end point data.\nOf these, 341 (81%) had laboratory-confirmed infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or epidemiologically linked exposure to a person with laboratory-confirmed infection; 56% (236 of 423) were enrolled within 1 day of symptoms starting.\nChange in symptom severity over 14 days did not differ between the hydroxychloroquine and placebo groups (difference in symptom severity: relative, 12%; absolute, -0.27 point [95% CI, -0.61 to 0.07 point]; P\u00a0= 0.117).\nAt 14 days, 24% (49 of 201) of participants receiving hydroxychloroquine had ongoing symptoms compared with 30% (59 of 194) receiving placebo (P\u00a0= 0.21).\nMedication adverse effects occurred in 43% (92 of 212) of participants receiving hydroxychloroquine versus 22% (46 of 211) receiving placebo (P\u00a0< 0.001).\nWith placebo, 10 hospitalizations occurred (2 non-COVID-19-related), including 1 hospitalized death.\nWith hydroxychloroquine, 4 hospitalizations occurred plus 1 nonhospitalized death (P\u00a0= 0.29).\nOnly 58% of participants received SARS-CoV-2 testing because of severe U.S. testing shortages.\nHydroxychloroquine did not substantially reduce symptom severity in outpatients with early, mild COVID-19.\nPRIMARY FUNDING SOURCE : Private donors.\n", "Evidence Map": {"Enrollment": [{"term": "Nonhospitalized Adults", "negation": "affirmed", "UMLS": {}, "start": 22, "end": 44}, {"term": "Early COVID-19", "negation": "affirmed", "UMLS": {}, "start": 50, "end": 64}, {"term": "adult outpatients", "negation": "affirmed", "UMLS": {}, "start": 76, "end": 93}, {"term": "Symptomatic , nonhospitalized adults", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 36}, {"term": "laboratory-confirmed COVID-19", "negation": "affirmed", "UMLS": {}, "start": 42, "end": 71}, {"term": "probable COVID-19", "negation": "affirmed", "UMLS": {}, "start": 75, "end": 92}, {"term": "high-risk exposure", "negation": "affirmed", "UMLS": {}, "start": 97, "end": 115}, {"term": "laboratory-confirmed infection with severe acute respiratory syndrome coronavirus 2 ( SARS-CoV-2 )", "negation": "affirmed", "UMLS": {}, "start": 28, "end": 126}, {"term": "epidemiologically linked exposure to a person", "negation": "affirmed", "UMLS": {}, "start": 130, "end": 175}, {"term": "laboratory-confirmed infection", "negation": "affirmed", "UMLS": {}, "start": 28, "end": 58}, {"term": "outpatients", "negation": "negated", "UMLS": {}, "start": 68, "end": 79}, {"term": "early , mild", "negation": "negated", "UMLS": {}, "start": 85, "end": 97}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 A Randomized Trial .", "Evidence Elements": {"Participant": [{"term": "Nonhospitalized Adults", "negation": "affirmed", "UMLS": {}, "start": 22, "end": 44}, {"term": "Early COVID-19", "negation": "affirmed", "UMLS": {}, "start": 50, "end": 64}], "Intervention": [{"term": "Hydroxychloroquine", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 18, "has_chemical": [{"text": "hydroxychloroquine", "maps_to": "C0020336:hydroxychloroquine", "start": 0, "end": 18}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "BACKGROUND", "Text": "No effective oral therapy exists for early coronavirus disease 2019 ( COVID-19 ) .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "OBJECTIVE", "Text": "To investigate whether hydroxychloroquine could reduce COVID-19 severity in adult outpatients .", "Evidence Elements": {"Participant": [{"term": "adult outpatients", "negation": "affirmed", "UMLS": {}, "start": 76, "end": 93}], "Intervention": [{"term": "hydroxychloroquine", "negation": "affirmed", "UMLS": {}, "start": 23, "end": 41, "has_chemical": [{"text": "hydroxychloroquine", "maps_to": "C0020336:hydroxychloroquine", "start": 0, "end": 18}], "has_relation": "N/A"}], "Outcome": [{"term": "COVID-19 severity", "negation": "affirmed", "UMLS": {}, "start": 55, "end": 72}], "Observation": [{"term": "reduce", "negation": "affirmed", "UMLS": {}, "start": 48, "end": 54}], "Count": []}, "Evidence Propositions": []}, {"Section": "DESIGN", "Text": "Randomized , double-blind , placebo-controlled trial conducted from 22 March through 20 May 2020 . ( ClinicalTrials.gov : NCT04308668 ) .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "SETTING", "Text": "Internet-based trial across the United States and Canada ( 40 states and 3 provinces ) .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "PARTICIPANTS", "Text": "Symptomatic , nonhospitalized adults with laboratory-confirmed COVID-19 or probable COVID-19 and high-risk exposure within 4 days of symptom onset .", "Evidence Elements": {"Participant": [{"term": "Symptomatic , nonhospitalized adults", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 36}, {"term": "laboratory-confirmed COVID-19", "negation": "affirmed", "UMLS": {}, "start": 42, "end": 71}, {"term": "probable COVID-19", "negation": "affirmed", "UMLS": {}, "start": 75, "end": 92}, {"term": "high-risk exposure", "negation": "affirmed", "UMLS": {}, "start": 97, "end": 115}], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "INTERVENTION", "Text": "Oral hydroxychloroquine ( 800 mg once , followed by 600 mg in 6 to 8 hours , then 600 mg daily for 4 more days ) or masked placebo .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "Oral hydroxychloroquine", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 23, "has_chemical": [{"text": "hydroxychloroquine", "maps_to": "C0020336:hydroxychloroquine", "start": 5, "end": 23, "has_route": ["oral"]}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "MEASUREMENTS", "Text": "Symptoms and severity at baseline and then at days 3 , 5 , 10 , and 14 using a 10-point visual analogue scale .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "Symptoms", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 8}, {"term": "severity", "negation": "affirmed", "UMLS": {}, "start": 13, "end": 21}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "MEASUREMENTS", "Text": "The primary end point was change in overall symptom severity over 14 days .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "overall symptom severity", "negation": "affirmed", "UMLS": {}, "start": 36, "end": 60}], "Observation": [{"term": "change", "negation": "affirmed", "UMLS": {}, "start": 26, "end": 32}], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "Of 491 patients randomly assigned to a group , 423 contributed primary end point data .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "Of these , 341 ( 81 % ) had laboratory-confirmed infection with severe acute respiratory syndrome coronavirus 2 ( SARS-CoV-2 ) or epidemiologically linked exposure to a person with laboratory-confirmed infection ; 56 % ( 236 of 423 ) were enrolled within 1 day of symptoms starting .", "Evidence Elements": {"Participant": [{"term": "laboratory-confirmed infection with severe acute respiratory syndrome coronavirus 2 ( SARS-CoV-2 )", "negation": "affirmed", "UMLS": {}, "start": 28, "end": 126}, {"term": "epidemiologically linked exposure to a person", "negation": "affirmed", "UMLS": {}, "start": 130, "end": 175}, {"term": "laboratory-confirmed infection", "negation": "affirmed", "UMLS": {}, "start": 28, "end": 58}], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "Change in symptom severity over 14 days did not differ between the hydroxychloroquine and placebo groups ( difference in symptom severity : relative , 12 % ; absolute , -0.27 point [ 95 % CI , -0.61 to 0.07 point ] ; P=0.117 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "hydroxychloroquine", "negation": "negated", "UMLS": {}, "start": 67, "end": 85, "has_chemical": [{"text": "hydroxychloroquine", "maps_to": "C0020336:hydroxychloroquine", "start": 0, "end": 18}], "has_relation": "N/A"}, {"term": "placebo", "negation": "negated", "UMLS": {}, "start": 90, "end": 97, "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}], "Outcome": [{"term": "Change in symptom severity", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 26}, {"term": "difference in symptom severity", "negation": "negated", "UMLS": {}, "start": 107, "end": 137}], "Observation": [{"term": "differ", "negation": "negated", "UMLS": {}, "start": 48, "end": 54}], "Count": []}, "Evidence Propositions": [{"Intervention": {"term": "hydroxychloroquine", "has_chemical": [{"text": "hydroxychloroquine", "maps_to": "C0020336:hydroxychloroquine", "start": 0, "end": 18}], "has_relation": "N/A"}, "Observation": "differ", "Outcome": "Change in symptom severity", "Count": ""}, {"Intervention": {"term": "placebo", "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}, "Observation": "differ", "Outcome": "Change in symptom severity", "Count": ""}]}, {"Section": "RESULTS", "Text": "At 14 days , 24 % ( 49 of 201 ) of participants receiving hydroxychloroquine had ongoing symptoms compared with 30 % ( 59 of 194 ) receiving placebo ( P = 0.21 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "hydroxychloroquine", "negation": "affirmed", "UMLS": {}, "start": 58, "end": 76, "has_chemical": [{"text": "hydroxychloroquine", "maps_to": "C0020336:hydroxychloroquine", "start": 0, "end": 18}], "has_relation": "N/A"}], "Outcome": [{"term": "ongoing symptoms", "negation": "affirmed", "UMLS": {}, "start": 81, "end": 97}], "Observation": [], "Count": [{"term": "24 % ( 49 of 201 ) of participants", "negation": "affirmed", "UMLS": {}, "start": 13, "end": 47}, {"term": "30 % ( 59 of", "negation": "affirmed", "UMLS": {}, "start": 112, "end": 124}]}, "Evidence Propositions": [{"Intervention": {"term": "hydroxychloroquine", "has_chemical": [{"text": "hydroxychloroquine", "maps_to": "C0020336:hydroxychloroquine", "start": 0, "end": 18}], "has_relation": "N/A"}, "Observation": "", "Count": "24 % ( 49 of 201 ) of participants", "Outcome": "ongoing symptoms"}]}, {"Section": "RESULTS", "Text": "Medication adverse effects occurred in 43 % ( 92 of 212 ) of participants receiving hydroxychloroquine versus 22 % ( 46 of 211 ) receiving placebo ( P < 0.001 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "hydroxychloroquine", "negation": "affirmed", "UMLS": {}, "start": 84, "end": 102, "has_chemical": [{"text": "hydroxychloroquine", "maps_to": "C0020336:hydroxychloroquine", "start": 0, "end": 18}], "has_relation": "N/A"}], "Outcome": [{"term": "Medication adverse effects", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 26}], "Observation": [], "Count": [{"term": "43 % ( 92 of 212 ) of participants", "negation": "affirmed", "UMLS": {}, "start": 39, "end": 73}, {"term": "22 % ( 46 of 211", "negation": "affirmed", "UMLS": {}, "start": 110, "end": 126}]}, "Evidence Propositions": [{"Intervention": {"term": "hydroxychloroquine", "has_chemical": [{"text": "hydroxychloroquine", "maps_to": "C0020336:hydroxychloroquine", "start": 0, "end": 18}], "has_relation": "N/A"}, "Observation": "", "Count": "43 % ( 92 of 212 ) of participants", "Outcome": "Medication adverse effects"}]}, {"Section": "RESULTS", "Text": "With placebo , 10 hospitalizations occurred ( 2 non-COVID-19-related ) , including 1 hospitalized death .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 5, "end": 12, "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}], "Outcome": [{"term": "hospitalizations", "negation": "affirmed", "UMLS": {}, "start": 18, "end": 34}, {"term": "non-COVID-19-related", "negation": "affirmed", "UMLS": {}, "start": 48, "end": 68}], "Observation": [], "Count": [{"term": "10", "negation": "affirmed", "UMLS": {}, "start": 15, "end": 17}, {"term": "2", "negation": "affirmed", "UMLS": {}, "start": 46, "end": 47}]}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "With hydroxychloroquine , 4 hospitalizations occurred plus 1 nonhospitalized death ( P = 0.29 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "hydroxychloroquine", "negation": "affirmed", "UMLS": {}, "start": 5, "end": 23, "has_chemical": [{"text": "hydroxychloroquine", "maps_to": "C0020336:hydroxychloroquine", "start": 0, "end": 18}], "has_relation": "N/A"}], "Outcome": [{"term": "hospitalizations", "negation": "affirmed", "UMLS": {}, "start": 28, "end": 44}, {"term": "nonhospitalized death", "negation": "affirmed", "UMLS": {}, "start": 61, "end": 82}], "Observation": [], "Count": [{"term": "4", "negation": "affirmed", "UMLS": {}, "start": 26, "end": 27}, {"term": "1", "negation": "affirmed", "UMLS": {}, "start": 59, "end": 60}]}, "Evidence Propositions": []}, {"Section": "LIMITATION", "Text": "Only 58 % of participants received SARS-CoV-2 testing because of severe U.S . testing shortages .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "SARS-CoV-2 testing", "negation": "affirmed", "UMLS": {}, "start": 35, "end": 53, "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "CONCLUSION", "Text": "Hydroxychloroquine did not substantially reduce symptom severity in outpatients with early , mild COVID-19 .", "Evidence Elements": {"Participant": [{"term": "outpatients", "negation": "negated", "UMLS": {}, "start": 68, "end": 79}, {"term": "early , mild", "negation": "negated", "UMLS": {}, "start": 85, "end": 97}], "Intervention": [{"term": "Hydroxychloroquine", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 18, "has_chemical": [{"text": "hydroxychloroquine", "maps_to": "C0020336:hydroxychloroquine", "start": 0, "end": 18}], "has_relation": "N/A"}], "Outcome": [{"term": "symptom severity", "negation": "negated", "UMLS": {}, "start": 48, "end": 64}], "Observation": [{"term": "substantially reduce", "negation": "negated", "UMLS": {}, "start": 27, "end": 47}], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "PRIMARY FUNDING SOURCE : Private donors .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}]}